Advertisement

Topics

Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017

04:08 EDT 3 Aug 2017 | PR Newswire

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the quarter and six months ended June 30, 2017 after the market closes on Thursday, August 10, 2017. Biocept management will hold a conference call for the investment community at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the results and answer questions.

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting https://www.webcaster4.com/Webcast/Page/1271/22128.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10111122.  A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.

About Biocept Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  Biocept's patented Target Selectorâ„¢ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-to-release-second-quarter-2017-financial-results-and-host-investor-conference-call-on-august-10-2017-300498896.html

SOURCE Biocept, Inc.

NEXT ARTICLE

More From BioPortfolio on "Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...